ABOUT US

ABOUT US

MISSION STATEMENT

Translating Science Into Lifesaving Tools

GestVision, Inc. is a biotechnology company committed to securing safer pregnancies by fearlessly challenging the status quo for women’s health.

 

We promise to deliver confidence to healthcare providers to make sound clinical decisions.

 

Our aim is to address the unmet medical needs in women’s health by bringing forth premium products based upon robust scientific discoveries.

LEADERSHIP TEAM

Wendy%20Davis_edited.jpg

Wendy L. Davis, MBA

Founder & Chief Executive Officer

Wendy Davis is the Founder and CEO of GestVision, Inc. Wendy has over 30 years of experience in biotechnology, cultivating novel opportunities from early stage inventions through commercialization and, where appropriate, FDA approval.

 

Before founding GestVision, Wendy held positions at HistoRx, Inc, a biotechnology company delivering diagnostic solutions to guide treatment decisions in oncology (acquired by Novartis), Curagen Corporation, the University of South Florida Moffitt Cancer Center and Cytogen Corporation. 

 

Wendy holds an MBA from Yale University and a BA from Swarthmore College.

Emily Moore

Emily Moore, MPH

VP, Business & Commercial Operations

Emily Moore is Vice President of Business and Commercial Operations for GestVision, Inc. She has more than 20 years of experience in creating and implementing growth strategies, leading the process from strategy development to execution of profitable business plans.

 

Over the past 15 years, Emily has focused her career on bringing disruptive healthcare innovations to market to improve patient access and drive down the cost of care. Before joining GestVision, Inc., Emily held positions at Temptime Corporation, Magellan Health and Praxair, Inc.

 

Emily holds an MPH from Columbia University and a BA from Wellesley College.

Hugh Fryer is Vice President of Research and Development for GestVision, Inc.

 

With more than 30 years of experience in research and management related to clinical therapeutics and diagnostics, Hugh has held positions at Sekisui Diagnostics, American Diagnostica and Curagen Corporation as a strategic leader responsible for developing new product portfolio pipelines. He has been responsible for leading R&D sites both here in the United States and overseas.

 

He holds a PhD from Yale University and a BS from the University of California San Diego.

Hugh Fryer, PhD

VP, Research & Development

BOARD OF DIRECTORS

Wendy L. Davis, MBA 
Founder and CEO

 

Robert Auerbach, MD, FACOG 
CooperSurgical

 

Heiner Dreismann, PhD 
Former President and CEO, Roche Molecular Systems

SCIENTIFIC ADVISORY BOARD

Catalin Buhimschi, MD, MBA
Maternal Fetal Medicine, The University of Illinois at Chicago

 

Irina Buhimschi, MD
Professor of Obstetrics & Gynecology, Director, Division of Research, Perinatal Research Laboratory, The University of Illinois at Chicago

 

George Saade, MD
Chief of Obstetrics and Maternal Fetal Medicine; Director, Perinatal Research Division, Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, University of Texas Medical Branch